Open AccessCD20 Expression in Normal Canine B Cells and in Canine non-Hodgkin Lymphoma
Author(s) -
Cristan M. Jubala,
John Wojcieszyn,
V. E. Valli,
David M. Getzy,
Susan Fosmire,
David G. Coffey,
Donald Bellgrau,
Jaime F. Modiano
Publication year - 2005
Publication title -
veterinary pathology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.794
H-Index - 89
eISSN - 1544-2217
pISSN - 0300-9858
DOI - 10.1354/vp.42-4-468
Subject(s) - canine lymphoma , antibody , cd20 , lymphoma , spleen , pathology , epitope , peripheral blood mononuclear cell , lymph node , antigen , b cell , biology , immunology , medicine , in vitro , biochemistry
We examined the expression of CD20 in normal canine peripheral blood mononuclear cells, normal canine spleen, and canine non-Hodgkin lymphoma (NHL) to determine the feasibility of using this antigen as a diagnostic aid and as a possible target for therapy. An antibody generated against a C-terminal (intracytoplasmic) epitope of human CD20 recognized proteins of 32-36 kd in normal and malignant canine lymphocytes. This antibody showed restricted membrane binding in a subset of lymphocytes in peripheral blood, in the B-cell regions from a normal canine spleen and lymph node, and in malignant cells from 19 dogs with B-cell NHL, but not from 15 dogs with T-cell NHL. The patterns of CD20 reactivity in these samples overlapped those seen using an antibody that recognizes canine CD79a. This anti-CD20 antibody is therefore suitable as an aid to phenotype canine NHL. In contrast, normal canine B cells were not recognized by any of 28 antibodies directed against the extracellular domains of human CD20 (including the chimeric mouse-human antibody Rituximab) or by any of 12 antibodies directed against the extracellular domains of mouse CD20. Thus, the use of CD20 as a therapeutic target will require the generation of specific antibodies against the extracellular domains of canine CD20.